SELECT trial: what semaglutide cardiovascular data actually shows
Research & educational use only. This content is not medical advice. Consult a qualified healthcare professional before using any peptide compound.
The SELECT trial is one of the more important recent results because it tested cardiovascular outcomes in people with established cardiovascular disease and overweight or obesity, without diabetes. The headline was roughly a 20 percent reduction in major adverse cardiovascular events versus placebo.
What I want to discuss is the nuance: the absolute risk reduction, the role of weight loss versus direct vascular effects, and why a cardiovascular outcomes trial is a much stronger form of evidence than a surrogate-endpoint study. This is why semaglutide sits at evidence Tier 1.
12